{
    "root": "f550d2ba-49ac-4a3b-95db-692b468af479",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "Human Prescription Drug Label",
    "name": {
        "text": "DEXMEDETOMIDINE HYDROCHLORIDE"
    },
    "value": "20240814",
    "ingredients": [
        {
            "name": "DEXMEDETOMIDINE HYDROCHLORIDE",
            "code": "1018WH7F9I"
        },
        {
            "name": "SODIUM CHLORIDE",
            "code": "451W47IQ8X"
        },
        {
            "name": "METHIONINE",
            "code": "AE28F7PNPL"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R"
        }
    ],
    "indications": "dexmedetomidine hydrochloride 0.9 % sodium chloride injection alpha 2 -adrenergic receptor agonist indicated : \u2022 sedation initially intubated mechanically ventilated adult patients treatment intensive care setting . administer dexmedetomidine hydrochloride 0.9 % sodium chloride injection continuous infusion exceed 24 hours . ( 1.1 ) \u2022 sedation non-intubated adult patients prior and/or surgical procedures . ( 1.2 )",
    "contraindications": "\u2022 individualize titrate dexmedetomidine hydrochloride 0.9 % sodium chloride injection dosing desired effect . ( 2.1 ) \u2022 administer dexmedetomidine hydrochloride 0.9 % sodium chloride injection using controlled infusion device . ( 2.1 ) \u2022 200 mcg/50ml 400 mcg/100 ml single-dose bottles , require dilution prior . ( 2.4 ) \u2022 adult intensive care unit sedation : initiate one mcg/kg 10 minutes , followed maintenance infusion 0.2 0.7 mcg/kg/ hour . ( 2.2 ) \u2022 adult procedural sedation : initiate one mcg/kg 10 minutes , followed maintenance infusion initiated 0.6 mcg/kg/ hour titrated achieve desired effect doses ranging 0.2 1 mcg/kg/ hour . ( 2.2 ) \u2022 alternative doses : recommended patients 65 years age awake fiberoptic intubation patients . ( 2.2 )",
    "warningsAndPrecautions": "store 20\u00b0c 25\u00b0c ( 68\u00b0f 77\u00b0f ) [ usp controlled room temperature ] . product discolored precipitate matter present . dexmedetomidine hydrochloride 0.9 % sodium chloride injection clear colorless solution . strength based dexmedetomidine base . discard unused portion . unit sale concentration ndc 52536-125-01 single-dose clear glass bottle 200 mcg/50 ml ( 4 mcg/ml ) ndc 52536-125-10 carton 10 single-dose clear glass bottles 200 mcg/50 ml ( 4 mcg/ml ) ndc 52536-126-01 single-dose clear glass bottle 400 mcg/100 ml ( 4 mcg/ml ) ndc 52536-126-08 carton 8 single-dose clear glass bottles 400 mcg/100 ml ( 4 mcg/ml )",
    "adverseReactions": "none",
    "indications_original": "Dexmedetomidine hydrochloride in 0.9% sodium chloride injection is a alpha 2 -adrenergic receptor agonist indicated for: \u2022\u00a0Sedation of initially intubated and mechanically ventilated adult patients during treatment in an intensive care setting. Administer dexmedetomidine hydrochloride in 0.9% sodium chloride injection by continuous infusion not to exceed 24 hours. ( 1.1 ) \u2022\u00a0Sedation of non-intubated adult patients prior to and/or during surgical and other procedures. ( 1.2 )",
    "contraindications_original": "\u2022\u00a0Individualize and titrate dexmedetomidine hydrochloride in 0.9% sodium chloride injection dosing to desired clinical effect. ( 2.1 ) \u2022\u00a0Administer dexmedetomidine hydrochloride in 0.9% sodium chloride injection using a controlled infusion device. ( 2.1 ) \u2022\u00a0The 200 mcg/50mL and 400 mcg/100 mL single-dose bottles, do not require further dilution prior to administration. ( 2.4 ) \u2022 For Adult Intensive Care Unit Sedation : Initiate at one mcg/kg over 10 minutes , followed by a maintenance infusion of 0.2 to 0.7 mcg/kg/ hour . ( 2.2 ) \u2022 For Adult Procedural Sedation : Initiate at one mcg/kg over 10 minutes , followed by a maintenance infusion initiated at 0.6 mcg/kg/ hour and titrated to achieve desired clinical effect with doses ranging from 0.2 to 1 mcg/kg/ hour . ( 2.2 ) \u2022 Alternative Doses : Recommended for patients over 65 years of age and awake fiberoptic intubation patients. ( 2.2 )",
    "warningsAndPrecautions_original": "Store at 20\u00b0C to 25\u00b0C (68\u00b0F to 77\u00b0F) [See USP Controlled Room Temperature]. Do not use if product is discolored or if precipitate matter is present. Dexmedetomidine hydrochloride in 0.9% Sodium Chloride injection is a clear colorless solution. The strength is based on the dexmedetomidine base. Discard unused portion.\n                  \n                     \n                        \n                        \n                     \n                     \n                        \n                           \n                              Unit of Sale\n                              \n                           \n                           \n                              Concentration\n                              \n                           \n                        \n                        \n                           \n                              NDC 52536-125-01\n                              Single-dose clear glass bottle\n                           \n                           200 mcg/50 mL (4 mcg/mL)\n                           \n                        \n                        \n                           \n                              NDC 52536-125-10\n                              Carton of 10 single-dose clear glass bottles\n                           \n                           200 mcg/50 mL (4 mcg/mL)\n                           \n                        \n                        \n                           \n                              NDC 52536-126-01\n                              Single-dose clear glass bottle\n                           \n                           400 mcg/100 mL (4 mcg/mL)\n                           \n                        \n                        \n                           \n                              NDC 52536-126-08\n                              Carton of 8 single-dose clear glass bottles\n                           \n                           400 mcg/100 mL (4 mcg/mL)",
    "adverseReactions_original": "None"
}